Business & Tech
Framingham Company To Present at Biotech Conference
Alzheon is a clinical-stage biopharmaceutical company in Framingham.

Alzheon, Inc., a clinical-stage biopharmaceutical company focused on developing new medicines for patients suffering from Alzheimer’s disease and other neurological and psychiatric disorders,will present at a Biotech conference on Thursday.
Alzheon founder and CEO Martin Tolar, M.D., Ph.D., will present at the 22nd Annual NewsMakers in the Biotech Industry Conference at the Millennium Broadway Hotel on Thursday, Sept. 10 in New York City.
Alzheon, Inc., based in Framingham, is committed to developing innovative medicines for patients suffering from Alzheimer’s disease and other neurological and psychiatric disorders.
Find out what's happening in Framinghamfor free with the latest updates from Patch.
Its mission is to apply our discovery platform and development experience to unlock new classes of therapeutics that make a difference in patients’ lives by directly addressing the underlying pathology of devastating neurodegenerative disorders.
Get more local news delivered straight to your inbox. Sign up for free Patch newsletters and alerts.